Arjo's Clean Q3 Is a Tariff Refund in Disguise — and the Real Test Starts in 2027

The headline vs. the fine print

Arjo reported 6% organic growth in Q3 2026, and on the surface it looks like the turnaround is finally gaining traction. Gross margin rose 1.9 percentage points year over year, adjusted EBIT nearly jumped to SEK 247 million from SEK 165 million, and operating cash flow improved to SEK 485 million. CEO Andreas Elgaard did not hide his satisfaction: “the growth is what sticks out this quarter with a 6% organic growth” — Andreas Elgaard, President and CEO · 2026-10-22. But the fine print matters. Roughly SEK 35 million of the gross-margin gain came from a U.S. tariff refund, and FX added another SEK 16 million to gross profit and SEK 15 million to adjusted EBIT. Strip both out, and adjusted EBIT was SEK 195 million with a 6.8% margin, better than 6.2% last year but hardly a step-change. CFO Christofer Carlsson was explicit: “Excluding FX and the U.S. tariff reimbursement, adjusted EBIT amounted to SEK 195 million with an improved EBIT margin of 6.8% compared to 6.2% last year.” — Christofer Carlsson, CFO · 2026-10-22 That is the real number to anchor on. Working capital days rose to 88 from 82, and cash conversion slipped to 100.4% from 105%, though it remains above the 80% target on a rolling 12-month basis. Net debt to adjusted EBITDA fell to 2.2x, and the equity ratio edged up to 50.3%. The balance sheet is not the problem. The P&L quality is.

What changed: a number, finally

The bigger news is not the quarter but the Capital Markets Day a few weeks earlier. Arjo put a hard number on its turnaround: profit improvement of SEK 350 million by H1 2029, coming from operating-model changes, procurement, commercial excellence, and a leaner cost structure. Elgaard called it real and within management's control: “we have a SEK 350 million commitment of profit improvements in -- until H1 2029” — Andreas Elgaard, President and CEO · 2026-10-22. That is a meaningful shift from the prior call, when an analyst pressed him on whether 2026 would be “yet another lost year when it comes to margins for Arjo” — Kristofer Liljeberg-Svensson, Analyst · 2026-01-30. Back then Elgaard insisted “you cannot say that you need to wait another year” — Andreas Elgaard, President and CEO · 2026-01-30. Now there is a quantified plan, new financial targets promised for Q1 2027, and a new segment structure split into North America, Europe, and international/distributor-led markets. The restructuring cost is real: SEK 41 million in the quarter versus SEK 13 million last year, with the majority of the programme landing over the next 18 months. Elgaard framed the goal as building a scalable platform, not just a cost-cutting exercise.

The strategy is really all about a plan to put Arjo back on track... focusing on where we have our strengths and building a more focused and lean organization that is concentrating where we have the right to play.

The global tariff wave behind the margin

Arjo's tariff refund is not a company-specific win. It is part of a broad 2026 reversal in U.S. trade costs that has lifted industrial and consumer names across the market. Global keywords show net tariff refunds surging in Q3 2026, and recent reporters from Deckers to Hasbro to Fiskars all flagged similar recoveries. For Arjo, the refund flattered gross margin by 1.6 percentage points, but the underlying mix was genuinely better: capital sales grew strongly, led by Patient Handling. Still, the market should not capitalise a one-off refund. The same global wave that giveth can taketh away if trade policy shifts again. And the old headwind has not disappeared: transportation costs were still higher across all categories, echoing the prior quarter when Carlsson said “I would say transportation cost is actually higher” — Christofer Carlsson, Chief Financial Officer · 2026-07-14. That is a recurring cost line, not a one-quarter blip. The global fuel-cost backdrop remains volatile, with high fuel costs still a live theme for industrial shippers.

What management stopped talking about

The most telling shift is what fell out of the narrative. In Q1 2026, flu season was the top company keyword, and analysts grilled management on hospitalisation trends. In the Q3 call it barely appears until the Q&A, when an analyst asks whether a normal flu season could help Q4. Elgaard's answer is a warning: “it can really make or break the fourth quarter” — Andreas Elgaard, President and CEO · 2026-10-22. The theme has not gone away; it has gone dormant, and that makes Q4 guidance fragile. The same is true of price pressure in the DVT business, which dominated prior calls. Management now sounds more confident that the worst is past, but the competitive dynamics have not structurally changed. Meanwhile, a fresh negative emerged: Arjo wrote down its investments in Atlas Mobility and Veplas to zero, producing a SEK 62 million negative revaluation. Carlsson disclosed that “both investments now have a carrying value of 0” — Christofer Carlsson, CFO · 2026-10-22. That is a company-unique hit the headline growth does not capture.

The honest read

Arjo is not out of the woods, but it is finally behaving like a company with a plan. The 6% organic growth and patient-handling momentum are real. The SEK 350 million profit-improvement target is a credible down payment on a better margin structure. But the quarter's optics are flattered by tariff refunds and FX, the restructuring bill is mounting, and the flu season remains an unhedged swing factor for Q4. Investors should watch two things: whether the new financial targets in Q1 2027 are as concrete as the 350 million promise, and whether the underlying margin ex-refund continues to grind higher. If it does, the turnaround has legs. If it does not, the tariff refund will look like a one-quarter reprieve rather than a turning point.